Effects of Phosphodiesterase 4 Inhibition on Alveolariza Newborn Rats

PLoS ONE

3, e3445

DOI: 10.1371/journal.pone.0003445

Citation Report

#	Article	IF	Citations
1	Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents?. European Respiratory Journal, 2009, 33, 1236-1236.	6.7	4
3	Bronchopulmonary dysplasia and emphysema: in search of common therapeutic targets. Trends in Molecular Medicine, 2009, 15, 169-179.	6.7	49
4	Differential expression of cyclic nucleotide phosphodiesterases 4 in developing rat lung. Developmental Dynamics, 2010, 239, 2470-2478.	1.8	5
5	Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L56-L67.	2.9	41
6	Antenatal Phosphodiesterase 4 Inhibition Restores Postnatal Growth and Pulmonary Development in a Model of Chorioamnionitis in Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 620-628.	2.5	2
8	Effect of Two Models of Intrauterine Growth Restriction on Alveolarization in Rat Lungs: Morphometric and Gene Expression Analysis. PLoS ONE, 2013, 8, e78326.	2.5	33
9	Caffeine and Rolipram Affect Smad Signalling and TGF-Î²1 Stimulated CTGF and Transgelin Expression in Lung Epithelial Cells. PLoS ONE, 2014, 9, e97357.	2.5	32
10	Ventilator-Associated Lung Injury. , 2015, , 917-945.		0
11	Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation. Toxicology and Applied Pharmacology, 2016, 298, 9-18.	2.8	16
12	Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2019, 32, 396-404.	1.4	5
13	Effects of intravenous phosphodiesterase inhibitors and corticosteroids on severe meconium aspiration syndrome. Journal of the Chinese Medical Association, 2019, 82, 568-575.	1.4	5
14	A Review on Currently Available Potential Therapeutic Options for COVID-19 . International Journal of General Medicine, 2020, Volume 13, 443-467.	1.8	15
15	Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism: Clinical and Experimental, 2020, 109, 154282.	3.4	50
16	Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. Scientific Reports, 2020, 10, 175.	3.3	10
17	Aurothioglucose enhances proangiogenic pathway activation in lungs from room air and hyperoxia-exposed newborn mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1165-L1171.	2.9	4
18	In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target. Trends in Pharmacological Sciences, 2021, 42, 772-788.	8.7	23
19	New Therapeutic Targets in Neonatal Pulmonary Hypertension. , 2022, 1, 158-169.		0
20	Acute Lung Functional and Airway Remodeling Effects of an Inhaled Highly Selective Phosphodiesterase 4 Inhibitor in Ventilated Preterm Lambs Exposed to Chorioamnionitis. Pharmaceuticals, 2023, 16, 29.	3.8	0